The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (66)
August 8, 2005
-
Maurer's Healthcare Insight (65)
July 11, 2005
-
Maurer's Healthcare Insight (64)
June 13, 2005
-
Maurer's Healthcare Insight (63)
May 30, 2005
-
Maurer's Healthcare Insight (62)
April 25, 2005
-
Maurer's Healthcare Insight (61)
March 28, 2005
-
Maurer's Healthcare Insight (60)
March 14, 2005
-
Maurer's Healthcare Insight (59)
December 6, 2004
-
Maurer's Healthcare Insight (58)
November 8, 2004
-
Maurer's Healthcare Insight (57)
October 11, 2004
-
Maurer's Healthcare Insight (56)
September 13, 2004
-
Maurer's Healthcare Insight (55)
July 26, 2004
-
Maurer's Healthcare Insight (54)
May 17, 2004
-
Maurer's Healthcare Insight (53)
April 19, 2004
-
Maurer's Healthcare Insight (52)
March 22, 2004
-
Maurer's Healthcare Insight (51)
March 1, 2004
-
Maurer's Healthcare Insight (50)
February 16, 2004
-
Maurer's Healthcare Insight (49)
January 26, 2004
-
Maurer's Healthcare Insight (48)
December 1, 2003
-
Maurer's Healthcare Insight (47)
November 3, 2003
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…